Eligibility of metastatic pancreatic adenocarcinoma (MPA) patients for first-line palliative intent nab-paclitaxel plus gemcitabine (NG) versus FOLFIRINOX (FIO)

被引：0
|
作者：
Peixoto, Renata D'Alpino
Renouf, Daniel John
Lim, Howard John
Cheung, Winson Y.
机构：
[1] BC Canc Agcy, Vancouver, BC, Canada
[2] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.259
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
259
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Comparative eligibility of metastatic pancreatic adenocarcinoma (MPA) patients for first-line palliative intent FOLFIRINOX (FIO) versus nab-paclitaxel plus gemcitabine (NG)
    Cheung, Winson Y.
    Renouf, Daniel John
    Lim, Howard John
    Peixoto, Renata D'Alpino
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX
    Peixoto, Renata D.
    Ho, Maria
    Renouf, Daniel J.
    Lim, Howard J.
    Gill, Sharlene
    Ruan, Jenny Y.
    Cheung, Winson Y.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2017, 40 (05): : 507 - 511
  • [3] FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer
    Ay, Seval
    Atci, Muhammed Mustafa
    Arikan, Rukiye
    Dulgar, Ozgecan
    Ozyukseler, Deniz Tataroglu
    Paksoy, Nail
    Dogan, Izzet
    Oztosun, Bugra
    Tastekin, Didem
    Oven, Basak Bala
    Gumus, Mahmut
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (07) : 465 - 471
  • [4] Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
    Klein-Brill, Avital
    Amar-Farkash, Shlomit
    Lawrence, Gabriella
    Collisson, Eric A.
    Aran, Dvir
    JAMA NETWORK OPEN, 2022, 5 (06) : E2216199
  • [5] Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
    Jihoon Kang
    Inhwan Hwang
    Changhoon Yoo
    Kyu-pyo Kim
    Jae Ho Jeong
    Heung-Moon Chang
    Sang Soo Lee
    Do Hyun Park
    Tae Jun Song
    Dong Wan Seo
    Sung Koo Lee
    Myung-Hwan Kim
    Seung-Mo Hong
    Sang Hyun Shin
    Dae Wook Hwang
    Ki Byung Song
    Jae Hoon Lee
    Song Cheol Kim
    Baek-Yeol Ryoo
    Investigational New Drugs, 2018, 36 : 732 - 741
  • [6] Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
    Kang, Jihoon
    Hwang, Inhwan
    Yoo, Changhoon
    Kim, Kyu-pyo
    Jeong, Jae Ho
    Chang, Heung-Moon
    Lee, Sang Soo
    Park, Do Hyun
    Song, Tae Jun
    Seo, Dong Wan
    Lee, Sung Koo
    Kim, Myung-Hwan
    Hong, Seung-Mo
    Shin, Sang Hyun
    Hwang, Dae Wook
    Song, Ki Byung
    Lee, Jae Hoon
    Kim, Song Cheol
    Ryoo, Baek-Yeol
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (04) : 732 - 741
  • [7] Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
    Di Costanzo, Francesco
    Di Costanzo, Federica
    Antonuzzo, Lorenzo
    Mazza, Ernesto
    Giommoni, Elisa
    CANCERS, 2023, 15 (02)
  • [8] First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population
    Hatashima, Alycia
    Arango, Matthew J.
    Reardon, Joshua
    Freeman, Tracelyn
    Williams, Terence
    McLaughlin, Eric M.
    Abushahin, Laith
    FUTURE ONCOLOGY, 2022, 18 (20) : 2521 - 2532
  • [9] NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer
    Nichetti, Federico
    Rota, Simone
    Ambrosini, Paolo
    Pircher, Chiara
    Gusmaroli, Eleonora
    Busset, Michele Droz Dit
    Pusceddu, Sara
    Sposito, Carlo
    Coppa, Jorgelina
    Morano, Federica
    Pietrantonio, Filippo
    Di Bartolomeo, Maria
    Mariani, Luigi
    Mazzaferro, Vincenzo
    de Braud, Filippo
    Niger, Monica
    JAMA NETWORK OPEN, 2024, 7 (01)
  • [10] FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study
    Servetto, Alberto
    Santaniello, Antonio
    Napolitano, Fabiana
    Foschini, Francesca
    Marciano, Roberta
    Cascetta, Priscilla
    Amato, Anna Rita
    Augurio, Maria Rosaria
    Maresca, Lucia
    De Placido, Pietro
    De Placido, Sabino
    Formisano, Luigi
    Bianco, Roberto
    FUTURE ONCOLOGY, 2022, 18 (21) : 2643 - 2654
12345